Fidelity Management and Research Company
-
Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year
The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
-
Allogene raises $120M for ‘off-the-shelf’ CAR-T development
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier’s UCART19 and clinical development of its own allogeneic CAR-Ts next year.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Fulcrum Therapeutics raises $80M to develop muscular dystrophy drug
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.
-
Heal adds investment from Fidelity in Series B round on the, er, heels of Series A
No sooner did Heal close a Series A round in October that it added another $14.8 million from Fidelity Management and Research Company. Here are a few things that make this move interesting.